Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Development of a universal internal positive control.

Kavlick MF.

Biotechniques. 2018 Nov;65(5):275-280. doi: 10.2144/btn-2018-0034.

2.

Development of a triplex mtDNA qPCR assay to assess quantification, degradation, inhibition, and amplification target copy numbers.

Kavlick MF.

Mitochondrion. 2019 May;46:41-50. doi: 10.1016/j.mito.2018.09.007. Epub 2018 Sep 25.

PMID:
30261278
3.

Internal validation of human mitochondrial DNA quantification using real-time PCR.

Sprouse ML, Phillips NR, Kavlick MF, Roby RK.

J Forensic Sci. 2014 Jul;59(4):1049-56. doi: 10.1111/1556-4029.12477. Epub 2014 Apr 7.

PMID:
24708529
4.

Determination of an effective housekeeping gene for the quantification of mRNA for forensic applications.

Moreno LI, Tate CM, Knott EL, McDaniel JE, Rogers SS, Koons BW, Kavlick MF, Craig RL, Robertson JM.

J Forensic Sci. 2012 Jul;57(4):1051-8. doi: 10.1111/j.1556-4029.2012.02086.x. Epub 2012 Feb 6.

PMID:
22309221
5.

Quantification of human mitochondrial DNA using synthesized DNA standards.

Kavlick MF, Lawrence HS, Merritt RT, Fisher C, Isenberg A, Robertson JM, Budowle B.

J Forensic Sci. 2011 Nov;56(6):1457-63. doi: 10.1111/j.1556-4029.2011.01871.x. Epub 2011 Sep 2.

PMID:
21883207
6.

Evaluation of circular DNA substrates for whole genome amplification prior to forensic analysis.

Tate CM, Nuñez AN, Goldstein CA, Gomes I, Robertson JM, Kavlick MF, Budowle B.

Forensic Sci Int Genet. 2012 Mar;6(2):185-90. doi: 10.1016/j.fsigen.2011.04.011. Epub 2011 May 12.

PMID:
21570374
8.

Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants.

Matsumi S, Kosalaraksa P, Tsang H, Kavlick MF, Harada S, Mitsuya H.

AIDS. 2003 May 23;17(8):1127-37.

PMID:
12819513
9.

Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.

Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G, Yarchoan R, Wilson WH.

Blood. 2003 Jun 15;101(12):4653-9. Epub 2003 Feb 27.

10.

A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.

Yoshimura K, Kato R, Kavlick MF, Nguyen A, Maroun V, Maeda K, Hussain KA, Ghosh AK, Gulnik SV, Erickson JW, Mitsuya H.

J Virol. 2002 Feb;76(3):1349-58.

11.

Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.

Gatanaga H, Suzuki Y, Tsang H, Yoshimura K, Kavlick MF, Nagashima K, Gorelick RJ, Mardy S, Tang C, Summers MF, Mitsuya H.

J Biol Chem. 2002 Feb 22;277(8):5952-61. Epub 2001 Dec 10.

12.

Fluorometric determination of 2'-beta-fluoro-2',3'-dideoxyadenosine 5'-triphosphate, the active metabolite of a new anti-human immunodeficiency virus drug, in human lymphocytes.

Dai F, Kelley JA, Zhang H, Malinowski N, Kavlick MF, Lietzau J, Welles L, Yarchoan R, Ford H Jr.

Anal Biochem. 2001 Jan 1;288(1):52-61.

PMID:
11141306
13.

Mutations in the HIV type 1 integrase of patients receiving long-term dideoxynucleoside therapy do not confer resistance to zidovudine.

Pilon AA, Marchand C, Kavlick MF, Bajaj K, Owen J, Mitsuya H, Pommier Y.

AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1417-22.

PMID:
11018861
14.

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.

Falloon J, Piscitelli S, Vogel S, Sadler B, Mitsuya H, Kavlick MF, Yoshimura K, Rogers M, LaFon S, Manion DJ, Lane HC, Masur H.

Clin Infect Dis. 2000 Feb;30(2):313-8.

PMID:
10671334
15.

In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues.

Yoshimura K, Feldman R, Kodama E, Kavlick MF, Qiu YL, Zemlicka J, Mitsuya H.

Antimicrob Agents Chemother. 1999 Oct;43(10):2479-83.

16.

JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.

Yoshimura K, Kato R, Yusa K, Kavlick MF, Maroun V, Nguyen A, Mimoto T, Ueno T, Shintani M, Falloon J, Masur H, Hayashi H, Erickson J, Mitsuya H.

Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8675-80.

17.
19.

HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination.

Yusa K, Kavlick MF, Kosalaraksa P, Mitsuya H.

Antiviral Res. 1997 Dec;36(3):179-89.

PMID:
9477118
20.

In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine.

Tanaka M, Srinivas RV, Ueno T, Kavlick MF, Hui FK, Fridland A, Driscoll JS, Mitsuya H.

Antimicrob Agents Chemother. 1997 Jun;41(6):1313-8.

21.

Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.

Kavlick MF, Shirasaka T, Kojima E, Pluda JM, Hui F Jr, Yarchoan R, Mitsuya H.

Antiviral Res. 1995 Oct;28(2):133-46.

PMID:
8585767
22.

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R, et al.

Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2398-402.

23.

Supplemental Content

Loading ...
Support Center